Phase 1 Lupus Trial, Recruiting NCT07115745 Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Condition: Lupus
Back to Lupus

Phase 1 Lupus Trial, Recruiting

NCT07115745
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with Systemic Lupus Erythematosus (SLE) — a disease where the immune system attacks the body:

  • You have been diagnosed with SLE based on specific medical guidelines (2019 ACR/EULAR criteria)
  • Certain specific antibodies related to SLE were found in your blood during screening
  • Your current treatments (steroids and immune-suppressing medicines) have not worked well enough, or you cannot tolerate them
  • Your SLE is currently active at the time of screening

For people with Inflammatory Myopathy (IIM) — a condition causing muscle inflammation:

  • You have been diagnosed with IIM based on specific medical guidelines (2017 ACR/EULAR criteria)
  • Your IIM is severe and has not responded to previous treatments
  • Steroids and immune-suppressing medicines have not worked well enough for you
  • Your disease is currently active

For people with Systemic Sclerosis (SSc) — a disease that causes hardening of the skin and can affect organs:

  • You have been diagnosed with SSc based on specific medical guidelines (2013 ACR/EULAR criteria)
  • Your previous treatments have not worked well enough, or you cannot tolerate them
  • Your SSc is getting worse and affects your skin and/or lungs

For people with Rheumatoid Arthritis (RA) — a condition causing joint inflammation:

  • Your RA has been difficult to treat
  • You have been diagnosed with RA based on specific medical guidelines (2010 ACR/EULAR criteria)
  • Your RA is currently active at screening and at the start of the trial
  • Standard treatments have not worked well enough, or you cannot tolerate them

Who may not be able to join:

For all participants:

  • You have another systemic autoimmune disease (a condition where the immune system attacks multiple parts of the body)
  • You are pregnant or currently breastfeeding
  • You have active Hepatitis B, Hepatitis C, or HIV
  • You have a history of cancer
  • You have an infection that is active or not well controlled
  • You have had certain heart or blood vessel problems in the 6 months before screening (confirm with trial site)
  • You have previously received CAR-T cell therapy (a type of immune cell treatment)
  • You have significant lung problems
  • Your organs (such as kidneys or liver) are not functioning well enough (confirm with trial site)
  • You have an active and serious condition affecting your brain or nervous system

Additionally, for people with SLE:

  • Your lupus was caused by a medication, or you have another autoimmune disease alongside SLE

Additionally, for people with IIM:

  • You have a different type of muscle disease that is not IIM
  • You have severe, lasting muscle damage

Additionally, for people with SSc:

  • You have high blood pressure in the arteries of your lungs caused by SSc that requires ongoing treatment to control
  • Your SSc is getting worse very rapidly, or you have a history of serious kidney disease related to SSc

Additionally, for people with RA:

  • You have another autoimmune disease alongside your RA

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Australian sites

Local Institution - 0007, Camperdown, New South Wales
Local Institution - 0008, Brisbane, Queensland
Local Institution - 0013, Clayton, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Registry
ClinicalTrials.gov
Start date
4 September 2025
Est. completion
15 March 2029

Where this trial is recruiting

🇦🇺 Australia 🇧🇷 Brazil 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇮🇱 Israel 🇵🇱 Poland 🇷🇴 Romania 🇪🇸 Spain 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants with treatment-emergent adverse events (TEAEs); Number of participants with serious AEs (SAEs); Number of participants with AEs of special interest (AESIs); Number of participants with laboratory abnormalities; Number of participants with Dose-Limiting Toxicities (DLTs); Number of participants with DLTs that occur during the DLT evaluation period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov